Updates from SABCS 2023 – HER2+ Breast Cancer
Tuesday January 16th 2024, 7:00-8:00 pm EST
Event Type: Virtual – Complimentary Webinar
- Summarize the most significant treatment advances in HER2+ Breast Cancer presented at SABCS 2023
- Describe key data presented at SABCS 2023 and the impact on Canadian practices
- To discuss current unmet needs in the management of HER2+ Breast Cancer
Meet the Updates from SABCS 2023 – HER2+ Breast Cancer Webinar Speakers
Dr. Jean-Pierre Ayoub (Speaker)
Dr. Jean-Pierre Ayoub is a Medical Oncologist and Clinical Assistant Professor of Medicine at the Centre hospitalier de l’Université de Montréal (CHUM). After completing his medical degree and Internal Medicine Residency at McGill University, Dr. Ayoub completed his subspecialty training in Medical Oncology at The University of Texas M.D Anderson Cancer Center in Houston, Texas. His clinical research interests include studies in breast and gastrointestinal malignancies. He has been a principal investigator or co-investigator in numerous studies involving these malignancies both with Industry and the National Cancer Institute of Canada – Clinical Trials Group.
He currently serves as the Centre Representative for the Centre hospitalier de l’université de Montréal for clinical trials with the National Cancer Institute of Canada – Clinical Trials Group and is a member of the Breast Disease Site Committee (Medical Oncology representative for the Centre hospitalier de l’université de Montréal) within the National Cancer Institute of Canada – Clinical Trials Group.
Dr. David Cescon (Chair)
Dr. David Cescon is a breast medical oncologist and clinician scientist at Princess Margaret Cancer Centre in Toronto. His clinical and academic interests include drug and biomarker development, and the application of circulating tumour DNA technologies in breast cancer. He is a member of multiple international breast cancer clinical trial initiatives and is the incoming chair of the Canadian Cancer Trials Group IND program.
This program has been made possible through unrestricted support from Seagen
All sales are final, refunds will not be accepted.
Please note mdBriefCase Group Inc. O/A Oncology Education cannot provide visa support for event attendees, including letters of invitation. Event attendees are solely responsible for obtaining any necessary documentation required for travel and participation in the event. No refunds shall be provided to individuals who are unable to attend.